SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:liu-128927"
 

Sökning: id:"swepub:oai:DiVA.org:liu-128927" > Clinical characteri...

Clinical characteristics and quality-of-life in patients surviving a decade of prostate cancer with bone metastases

Klaff, Rami (författare)
Linköpings universitet,Institutionen för klinisk och experimentell medicin,Medicinska fakulteten,Region Östergötland, Urologiska kliniken i Östergötland
Berglund, Anders (författare)
Eksatravagen 72, Uppsala, Sweden
Varenhorst, Eberhard (författare)
Linköpings universitet,Urologi,Hälsouniversitetet,Region Östergötland, Urologiska kliniken i Östergötland
visa fler...
Olov Hedlund, Per (författare)
Karolinska Institute Solna, Sweden
Nler, Morten J. (författare)
Aalborg University Hospital, Denmark
Sandblom, Gabriel (författare)
Karolinska Institutet
visa färre...
 (creator_code:org_t)
2015-07-14
2016
Engelska.
Ingår i: BJU International. - : WILEY-BLACKWELL. - 1464-4096 .- 1464-410X. ; 117:6, s. 904-913
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Objective To describe characteristics and quality-of-life (QoL), and to define factors associated with long-term survival in a subgroup of patients with prostate cancer with M1b disease. Patients and Methods The study was based on 915 patients from a prospective randomised multicentre trial (No. 5) by the Scandinavian Prostate Cancer Group, comparing parenteral oestrogen with total androgen blockade. Long-term survival was defined as patients having an overall survival of >= 10 years, and logistic regression models were constructed to identity clinical predictors of survival. QoL during follow-up was assessed using the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire - C30 version 1 (EORTC-C30) ratings. Results In all, 40 (4.4%) of the 915 men survived for >10 years. Factors significantly associated with increased likelihood of surviving for >10 years in the univariate analyses were: absence of cancer-related pain; Eastern Cooperative Oncology Group (ECOG) performance status of <2; negligible analgesic consumption; T-category of 1-2; prostate-specific antigen (PSA) level of <231 mu g/L; and a Soloway score of 1. In the multivariate analyses, ECOG performance status of <2, PSA level of <231 mu g/L, and Soloway score of 1, were all independent predictors of long-term survival. All subscales of the EORTC-C30 were higher in this group than for patients with short survival, but slowly declined over the decade. Conclusion A subgroup of patients with prostate cancer with M1b disease and certain characteristics showed a positive long-term response to androgen-deprivation therapy with an acceptable QoL over a decade or more. Independent predictors of long-term survival were identified as ECOG performance status of <2, limited extent of bone metastases (Soloway score of 1), and a PSA level of <231 mu g/L at the time of enrolment.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Nyckelord

prostate cancer; bone metastases; long-term survival; quality-of-life

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy